Literature DB >> 27498588

Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.

Angel Chao1, Ren-Chin Wu2, Shih-Ming Jung2, Yun-Shien Lee3, Shu-Jen Chen4, Yen-Lung Lu4, Chia-Lung Tsai5, Chiao-Yun Lin1, Yun-Hsin Tang1, Ming-Yu Chen1, Huei-Jean Huang1, Hung-Hsueh Chou1, Kuan-Gen Huang1, Ting-Chang Chang1, Tzu-Hao Wang6, Chyong-Huey Lai7.   

Abstract

OBJECTIVES: Synchronous endometrial and ovarian carcinomas (SEOCs) present gynecologic oncologists with a challenging diagnostic puzzle: discriminating between double primary cancers and single primary cancer with metastasis. We aimed to determine the clonal relationship between simultaneously diagnosed endometrial and ovarian carcinomas.
METHODS: Fourteen pairs of SEOCs of endometrioid type and two pairs of SEOCs with disparate histologic types (control for dual primary tumors) were subjected to massively parallel sequencing (MPS) and molecular inversion probe microarrays.
RESULTS: Thirteen of the 14 pairs of SEOCs harbored somatic mutations shared by both uterine and ovarian lesions, indicative of clonality. High degree of chromosomal instability in the tumors from 10 patients who received adjuvant chemotherapy, of whom 9 had synchronous carcinomas with significantly overlapping copy number alterations (CNAs), suggestive of single primary tumors with metastasis. The clonal relationship determined by genomic analyses did not agree with clinicopathological criteria in 11 of 14 cases. Minimal CNAs were identified in both ovarian and endometrial carcinomas in 4 patients, who did not receive adjuvant chemotherapy and experienced no recurrent diseases. In contrast, two of the 10 patients with chromosomally unstable cancers developed recurrent tumors.
CONCLUSION: Our findings support a recent paradigm-shifting concept that most SEOCs originate from a single tumor. It also casts doubt on the clinicopathological criteria used to distinguish between dual primary tumors and single primary tumor with metastasis. Testing of CNAs on SEOCs may help determining the need of adjuvant therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Copy number alteration; Endometrial cancer; Massively parallel sequencing (MPS); Ovarian cancer; Synchronous

Mesh:

Year:  2016        PMID: 27498588     DOI: 10.1016/j.ygyno.2016.07.114

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.

Authors:  Angel Chao; Chyong-Huey Lai; Tzu-Hao Wang; Shih-Ming Jung; Yun-Shien Lee; Wei-Yang Chang; Lan-Yang Yang; Fei-Chun Ku; Huei-Jean Huang; An-Shine Chao; Chin-Jung Wang; Ting-Chang Chang; Ren-Chin Wu
Journal:  J Mol Med (Berl)       Date:  2018-05-03       Impact factor: 4.599

Review 2.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

3.  Massively parallel sequencing and genome-wide copy number analysis revealed a clonal relationship in benign metastasizing leiomyoma.

Authors:  Ren-Chin Wu; An-Shine Chao; Li-Yu Lee; Gigin Lin; Shu-Jen Chen; Yen-Jung Lu; Huei-Jean Huang; Chi-Feng Yen; Chien Min Han; Yun-Shien Lee; Tzu-Hao Wang; Angel Chao
Journal:  Oncotarget       Date:  2017-07-18

4.  Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.

Authors:  Ren-Chin Wu; Ema Veras; Jeffrey Lin; Emily Gerry; Asli Bahadirli-Talbott; Alexander Baras; Ayse Ayhan; Ie-Ming Shih; Tian-Li Wang
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-11-21

5.  Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.

Authors:  Takashi Takeda; Kosuke Tsuji; Kouji Banno; Megumi Yanokura; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-30       Impact factor: 4.401

6.  Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.

Authors:  Casper Reijnen; Heidi V N Küsters-Vandevelde; Marjolijn J L Ligtenberg; Johan Bulten; Marloes Oosterwegel; Marc P L M Snijders; Sanne Sweegers; Joanne A de Hullu; Maria C Vos; Anneke A M van der Wurff; Anne M van Altena; Astrid Eijkelenboom; Johanna M A Pijnenborg
Journal:  Int J Cancer       Date:  2020-02-18       Impact factor: 7.396

7.  Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy.

Authors:  Kosuke Murakami; Yasushi Kotani; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

8.  Trends and outcomes of women with synchronous endometrial and ovarian cancer.

Authors:  Koji Matsuo; Hiroko Machida; Erin A Blake; Laura L Holman; Bobbie J Rimel; Lynda D Roman; Jason D Wright
Journal:  Oncotarget       Date:  2018-06-19

Review 9.  A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.

Authors:  Shuangfeng Chen; Yuebo Li; Lili Qian; Sisi Deng; Luwen Liu; Weihua Xiao; Ying Zhou
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

Review 10.  Potential for Mitochondrial DNA Sequencing in the Differential Diagnosis of Gynaecological Malignancies.

Authors:  Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.